Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Leases (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Current Leases data on record, last reported at $6.8 million in Q3 2025.

  • For Q3 2025, Current Leases fell 22.98% year-over-year to $6.8 million; the TTM value through Sep 2025 reached $6.8 million, down 22.98%, while the annual FY2024 figure was $9.1 million, 6.45% up from the prior year.
  • Current Leases reached $6.8 million in Q3 2025 per FHTX's latest filing, up from $6.2 million in the prior quarter.
  • Across five years, Current Leases topped out at $9.1 million in Q1 2025 and bottomed at $105000.0 in Q1 2021.
  • Average Current Leases over 5 years is $6.7 million, with a median of $7.0 million recorded in 2021.
  • Peak YoY movement for Current Leases: skyrocketed 7582.42% in 2021, then tumbled 31.88% in 2025.
  • A 5-year view of Current Leases shows it stood at $7.0 million in 2021, then decreased by 14.64% to $6.0 million in 2022, then soared by 42.68% to $8.5 million in 2023, then grew by 6.45% to $9.1 million in 2024, then dropped by 25.5% to $6.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $6.8 million in Q3 2025, $6.2 million in Q2 2025, and $9.1 million in Q1 2025.